Literature DB >> 21453881

Risk of colorectal cancer and small bowel adenocarcinoma in Crohn's disease: a population-based study from western Hungary 1977-2008.

Peter Laszlo Lakatos1, Gyula David, Tunde Pandur, Zsuzsanna Erdelyi, Gabor Mester, Mihaly Balogh, Istvan Szipocs, Csaba Molnar, Erzsebet Komaromi, Lajos S Kiss, Laszlo Lakatos.   

Abstract

BACKGROUND AND AIMS: Limited data are available on the incidence and predictors of colorectal (CRC) and small bowel adenocarcinoma (SBA) in patients with Crohn's disease (CD) from population-based cohorts. Since data are completely missing from Eastern Europe, our aim was to analyze the incidence and risk factors of CD associated CRC and SBA in the population-based, Veszprem province database, which included incident patients diagnosed between January 1, 1977 and December 31, 2008.
METHODS: The data of 506 incident CD patients were analyzed (age-at-diagnosis: 31.5, SD: 13.8 years). Both hospital and outpatient records were collected and comprehensively reviewed.
RESULTS: CRC was diagnosed in five patients (5/5758 person-year-duration) during follow-up, while no patients developed SBA in this cohort. Standardized incidence ratio (SIR) of CRC was not increased overall with five cases observed vs. 5.02 expected (SIR: 0.99, 95% CI: 0.41-2.39); however, there was a tendency for increased incidence in males (five cases observed vs. 2.56 expected; SIR: 1.95, 95% CI: 0.81-4.70). Age at onset of CD (p<0.001), male gender (p=0.022) and stenosing disease behavior at diagnosis (p<0.001) but not disease location were identified as risk factors for developing CRC in univariate analysis and Kaplan-Meier analysis. The cumulative risk for developing CRC after a disease duration of 20 years was 1.1% (95% CI: 0.6-1.7%).
CONCLUSIONS: The incidence of CRC and SBA was not increased in this population-based CD cohort. Age at onset of CD, male gender and stenosing disease behavior at diagnosis were identified as risk factors of CRC.
Copyright © 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21453881     DOI: 10.1016/j.crohns.2010.11.005

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  7 in total

1.  Elevated proinflammatory cytokine IL-17A in the adjacent tissues along the adenoma-carcinoma sequence.

Authors:  Guanglin Cui; Hang Yang; Jianbo Zhao; Aping Yuan; Jon Florholmen
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

2.  A telematic tool to predict the risk of colorectal cancer in white men and women: ColoRectal Cancer Alert (CRCA).

Authors:  Isabel de la Torre; Francisco Javier Díaz; Míriam Antón; Esteban Barragán; Joel Rodrigues; Celina Pires
Journal:  J Med Syst       Date:  2011-05-06       Impact factor: 4.460

Review 3.  Small bowel adenocarcinoma and Crohn's disease: any further ahead than 50 years ago?

Authors:  Caitlin Cahill; Philip H Gordon; Andrea Petrucci; Marylise Boutros
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 4.  Gastrointestinal Tract Disorders in Older Age.

Authors:  Igor Dumic; Terri Nordin; Mladen Jecmenica; Milica Stojkovic Lalosevic; Tomica Milosavljevic; Tamara Milovanovic
Journal:  Can J Gastroenterol Hepatol       Date:  2019-01-17

5.  Crohn's strictures open with anti-mycobacterial antibiotic therapy: A retrospective review.

Authors:  Rhys Collyer; Annabel Clancy; Gaurav Agrawal; Thomas J Borody
Journal:  World J Gastrointest Endosc       Date:  2020-12-16

6.  Small Bowel Adenocarcinoma Mimicking a Crohn's Attack.

Authors:  Arda Yavuz; Gülnihal Ay; Kübra Akan; Celal Ulaşoğlu; İlyas Tuncer
Journal:  Cureus       Date:  2021-06-18

Review 7.  Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Chelle L Wheat; Kindra Clark-Snustad; Beth Devine; David Grembowski; Timothy A Thornton; Cynthia W Ko
Journal:  Gastroenterol Res Pract       Date:  2016-05-16       Impact factor: 2.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.